A pilot study is testing whether 4 grams daily of krill oil—delivering 1,288 mg combined EPA and DHA plus astaxanthin and choline—can reduce chronic musculoskeletal pain in adults over 60. The three-month randomized controlled trial will track feasibility metrics alongside omega-3 blood levels, inflammation markers, and functional mobility measures in 40 participants. This represents a notably high omega-3 dosage compared to typical supplementation studies, which often use 1-2 grams daily. The choice of krill oil over standard fish oil reflects emerging evidence of superior bioavailability and additional anti-inflammatory compounds like astaxanthin. Chronic musculoskeletal pain affects mobility in roughly 40% of older adults, contributing significantly to disability and healthcare costs. Current pain management relies heavily on pharmaceuticals with limited efficacy and concerning side effect profiles in aging populations. If successful, this non-pharmacological approach could offer a safer alternative, particularly relevant given widespread omega-3 deficiency among older Americans. However, the pilot's small sample size and short duration limit definitive conclusions about clinical efficacy. The study's primary focus on feasibility rather than therapeutic outcomes positions it as preparatory work for larger definitive trials.